Clinical progress Revelation Biosciences is a clinical-stage biopharmaceutical focused on trained immunity with Gemini and AKI programs advancing toward regulatory pathways, presenting opportunities to engage CROs, pharma partners, and trial sponsors interested in nephrology and infection prevention.

Strategic partnerships Recent activity includes partnering with FDA on Gemini approval pathway and selecting Avance Clinical as CRO for the TITAN Phase 2/3 study, signaling openness to collaborations, outsourcing and co-development arrangements that can be leveraged for lead generation.

Clinical events The company actively participates in major conferences (Roth Conference, International Conference on Advances in Critical Care Nephrology) and hosts fireside chats, offering multiple touchpoints for executive outreach, investor relations, and sponsor positioning.

Funding posture With a funding total around eighty-four million dollars and revenue in the low single digits, there is potential for strategic licensing, grant opportunities, or milestone-based partnerships to accelerate trial timelines and expand clinical programs.

Operational scale Small to mid-size team (11-50 employees) combined with a growing CLINICAL trial footprint suggests partnering with CROs, CRO-like services, and specialized vendors to scale studies efficiently while managing cost and regulatory compliance.